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In renal transplantation, BK-virus (BKV)-associated nephropathy has emerged as a major
complication, with a prevalence of 1–10% and graft loss in >50% of cases. BKV is a
member of the polyomavirus family and rarely induces apparent clinical disease in the gen-
eral population. However, replication of polyomaviruses, associated with significant organ
disease, is observed in patients with acquired immunosuppression. Monitoring of specific
immunity combined with viral load could be used to individually assess the risk of viral
reactivation and virus control. We review the current knowledge on BKV-specific cellular
immunity and, more specifically, in immunocompromised patients. In the future, immune-
based therapies could allow us to treat and prevent BKV-associated nephropathy.
Keywords: polyomavirus, BK-virus, renal transplantation, anti-viral immunity, polyfunctionality
Introduction
BK-virus (BKV) is a human polyomavirus, first isolated in 1971, which belongs to a subfamily of
papovaviridae, and includes two main strains associated with human disease: BKV and JC-virus
(JCV). BKV is frequently responsible for irrelevant infection in the general population. Up to 85%
of adults have been exposed to the virus (as determined by serological testing), but recurrence of
the virus can be observed with immunosuppression, suggesting the presence of an asymptomatic,
latent infection. Except for children receiving a bone-marrow transplant, in most cases, in adults,
BKV infection corresponds to recurrence of the virus rather than a de novo infection after renal
transplantation. Human BKV has been associated with interstitial nephritis and ureteral stenosis
in the renal transplant, and hemorrhagic cystitis in recipients of a bone-marrow transplant. BKV
nephropathy, associated with viral recurrence, occurs in 1–10% of renal transplants and has emerged
as a major complication after renal transplantation, often leading to graft loss (1). The absence of a
non-nephrotoxic antiviral therapy leads to decrease immunosuppression to control viral replication,
but can lead to organ rejection. The role of the immune system in controlling this virus is still poorly
understood.
Incidence and Clinical Manifestations
Polyomaviruses in the General Population
Polyomaviruses are widespread in the general population but rarely induce apparent clinical disease
or pathology. This virus family coevolved with their hosts, as evidenced by their high prevalence and
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low morbidity (2, 3). Currently, the human polyomavirus family
consists of 10 members. The most common are polyomavirus
hominis 1 and 2, better known as BKV and JCV, respectively,
named after the initials of the patients from whom they were
first isolated in the 1970s (3). With a seroprevalence of more
than 80% for BKV and 50% for JCV, epidemiological stud-
ies in the general population indicate early and high expo-
sure to these polyomaviruses (4, 5). The primary infection is
often subclinical and without specific symptoms. Natural trans-
mission has not been fully clarified but likely occurs via the
respiratory or oral route. After a primary infection, BKV and
JCV are known to persist in the reno-urinary tract but mech-
anisms involved for the location of the virus in this epithelial
remain unknown (3). Asymptomatic urinary shedding of BKV
and JCV has been observed in 7 and 19% of healthy blood
donors aged 20–59 years, respectively, with median viral loads
of 3.51 and 4.64 log copies/mL, respectively. Neither BKV nor
JCV viremia has been detected in plasma in immunocompetent
individuals (4).
Polyomaviruses in Immunocompromised
Patients
Polyomaviruses are latent viruses that can replicate in patients
with acquired immunodeficiency. Significant organ diseases asso-
ciated with the replication of polyomaviruses have been observed
in patients with chronic acquired immunosuppression caused
by organ transplantation treatments, human immunodeficiency
virus (HIV) infection, or multiple sclerosis treated with natal-
izumab. BKV and JCV display similar behavior, with high preva-
lence in the general population and related diseases occurring
almost only in immunocompromised population. Similar mecha-
nisms for the replication control for these two viruses are required,
implicating the host response. However, BKV disease does not
directly correlate with the level of immunosuppression but usu-
ally depends on multiple complementary risk factors, including
host determinants (such as immune effectors), organ determi-
nants that favor BKV replication, or external modulators (such
as immunosuppressive drugs) (2). BKV is responsible for clinical
manifestations in, mainly, renal-transplant patients, and rarely
in heart- or liver-transplant patients, suggesting a role for local
factors, such as microinflammation and replication of BKV in
the renal epithelia. However, BKV-associated hemorrhagic cystitis
has also been observed in 5–15% of allogeneic hematopoietic
stem-cell transplants (1).
JCV does not induce disease in solid-organ transplants, but
is responsible for progressive multifocal leukoencephalopathy
(PML) inHIV patients and patients withmultiple sclerosis treated
with natalizumab. Despite specific cellular immunosuppression
in these patients, nephropathy caused by JCV or BKV is rare,
and BKV-associated PML or encephalitis is also rare. In addi-
tion, BKV has been rarely implicated in extrarenal pathologies
such as pneumonia, encephalitis, hepatitis, retinitis, capillary-
leak syndrome, or cancer (1, 3). Recently, the increased use of
immunosuppressors inmultiple sclerosis has been associated with
emerging immunocompromised-related infections. For example,
Lonergan et al. have already reported a higher incidence of BKV
reactivation in patients treated with natalizumab for multiple
sclerosis. However, the significance of BKV replication in the
absence of renal dysfunction is unclear (6).
Bone-Marrow Transplant Recipients
In clinical studies, hemorrhagic cystitis caused by BKV has been
observed in bone-marrow transplant recipients, mostly in young
people. It can be effectively treated with a specific antiviral ther-
apy such as cidofovir, leflunomide, or fluoroquinolone. However,
controlled clinical trials with cidofovir, leflunomide, and fluoro-
quinolones used to treat BKV-associated hemorrhagic cystitis are
needed to determine their true safety and efficacy in this patient
population (7). In this population, the potential nephrotoxicity of
cidofovir has caused a small number of acute renal failures.
Renal-Transplant Recipients
In renal transplantation, BKV reactivation has emerged as amajor
complication (in 1–10% of cases) (1). Its physiopathology is still
poorly understood. The first case of BKV-associated nephropathy
was described in 1995 andwas associated with the development of
immunosuppressive drugs such as tacrolimus andmycophenolate
mofetil (8). Currently, BKV remains an important issue in renal
transplantation and is a major cause of infectious disease that can
lead to graft loss (9, 10). BKV infections usually correspond to
viral reactivation from the urinary epithelium. These reactivations
occur in 1–10% of kidney-transplant (KT) recipients, and are
responsible for graft loss in 30–80% of cases (1). The loss is caused
on one hand by the toxic effects of the virus that cause desqua-
mation of dying epithelial cell in urine with alteration of their
nuclei (viral inclusions), and induce an inflammatory interstitial
response which infiltrates tubular interstitium. This is associated
with the development of fibrosis and tubular atrophy. On the
other hand when immunosuppression is decreased to control the
viral replication, the development of an acute tubular rejection
may occur. To date, the mechanisms involved in the development
of the inflammation of the kidney and the fibrosis associated
with BKV nephropathy are poorly understood. The phenotype
of infiltrating cells during BKV nephropathy and during acute
rejection is not different in re-enforcing the difficulty to diag-
nose BKV nephropathy from acute rejection. Moreover, these two
situations may occurred sequentially since the diagnosis of BKV
nephropathy will lead to a reduction of the general immunosup-
pression since BKV would reflect overimmunosuppression and
then will favor the development of an acute rejection which would
need to re-enforce immunosuppressive therapy. This highlights
the need to develop specific markers for the specific responses
to this virus, to avoid episodes of acute rejection, and to control
viral infection. Interestingly, the recurrence of BKV in the KT
population probably needs additional factors or injured tissue to
replicate. Despite its high rate of prevalence in this population,
only a fraction of KT recipients will develop viral reactivation
and BKV nephropathy. On the other hand, patients receiving a
similar immunosuppressive therapy after heart transplantation
less frequently develop BKV infection. In addition, despite an
important immunosuppression, some cases of BKV have been
identified in recipients of bone-marrow or cardiac transplants.
Because data are lacking on the pathophysiology of this viral
reactivation, therapeutic approaches have not been codified. Cur-
rently, no antiviral treatment is available except for cidofovir,
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which can cause renal toxicity, particularly in those with a renal
transplant (11, 12). In our experience, despite reducing the dose
of immunosuppression, the use of cidofovir adapted to renal
function is associated with a high rate of acute tubular necrosis.
Diagnosis of BKV-associated nephropathy is based on a
combination of non-specific histological lesions plus the pres-
ence of BKV viremia (plasma BKV-DNA with a viral load of
>104 copies/mL), or BKV viruria (urinary BKV-DNAwith a viral
load >107 copies/mL). Viruria is observed in 40% of KT recipi-
ents and usually precedes viremia (24% of cases) (13). Currently,
because of the poor outcome from BKV nephropathy, physicians
modulate immunosuppression before the occurrence of BKV
nephropathy by reducing immunosuppression. Early diagnosis is
essential to initiate treatment before the establishment of irre-
versible kidney damage (14).
Histological diagnosis is based on detecting signs of viral repli-
cation in epithelial cells (renal tubular cells and/or Bowman’s
capsular cells), and/or urinary-tract (“decoy cells”). These signs
include enlarged nuclei with smudgy chromatin changes, intranu-
clear viral inclusions, rounding, and detachment, which are asso-
ciated with an inflammatory infiltrate, necrosis, and/or fibrosis.
The infiltrate is mostly composed by mononuclear cells including
CD4 and CD8 lymphocytes and macrophages. The virus may be
identified by immunohistochemistry by staining for the Large-
SV40 tumor-antigen. The following patterns of BKV-associated
nephropathy have been described (1, 2, 11) (Figures 1A–C).
 Stage A – Moderate viral cytopathic changes within normal
renal parenchyma.
 Stage B–More severe cellular damageswith a combination of
viral cytopathic changes and focal/multifocal areas of tubular
atrophy, and/or interstitial fibrosis; inflammatory infiltrates,
and/or tubulitis (<25% for pattern B1; 25–50% for pattern
B2; >50% for pattern B3). The most important differential
diagnosis is acute rejection, which can also coexist with
BKV-associated nephropathy.
 Stage C – End-stage BKV-associated nephropathy, with
extensive interstitial fibrosis and tubular atrophy.
According to the histological lesions, the rate of graft loss varies
from 10% in stage A to 80% in stage C (1). Hirsch et al. (13)
analyzed the replication of BKV in more than 600 de novo KT
recipients within their first year post-transplant: viruria rate was
39.5% and viremia rate was 23.9%. Renal function at 1 year in
viremic patients was significantly impaired (median glomerular-
filtration rate 60.4 vs. 65.7mL/min; p= 0.032) with more fre-
quent acute-rejection episodes at 6months (13.0% vs. 6.1%,
p= 0.030). Risk factors for developing BKV viremia and/or BKV-
associated nephropathy have been identified and correspond
to high exposure to corticosteroids associated with tacrolimus
and/or mycophenolate mofetil (compared to a lower incidence
with cyclosporine A plus mycophenolate mofetil), being older,
and male gender (13, 15).
The intensity of immunosuppression is conventionally
proposed as a major determinant for the emergence of BKV-
associated nephropathy. However, questions regarding the
specific effects of immunosuppression (i.e., a direct effect or
individual susceptibility) remain unanswered (13). On the one
hand, patients with a conventional immunosuppressive therapy
(triple immunosuppression without depleting induction with
antibodies) may develop BKV replication and nephropathy, and
on the other hand, patients highly immunocompromised (with
depleting agents as an induction therapy for the graft or treated
with high dose of steroids for the acute rejection treatment) did
not. This suggests that individual susceptibility of patients might
favor or control BKV reactivation.
Elfadawy et al. (16) evaluated the impact of persistent or tran-
sient BKV viremia on renal-graft function. The mean onset of
BKV viremia was 4.03 2.5months post-transplant. The occur-
rence of BKV-associated nephropathy was limited to patients with
persistent high BKV viremia. At 1 year, graft function was signif-
icantly reduced and the rate of acute rejection was significantly
higher in KT recipients with high persistent or transient viremia.
In addition, patients with persistent low viremia were 3.1-fold
more likely to be cleared of the virus compared to those with per-
sistent high viremia (hazard ratio= 3.1; p= 0.001), which suggests
that potential control of the virus by the host’s immune system is
associated with a low BKV viral load. This finding suggests that
mechanisms other than direct tissue invasion by BKV may be
responsible for graft dysfunction as well as permissive factors or
mechanisms that favor the clearance of the virus and/or activation
of the immune system might participate to the graft dysfunction.
FIGURE 1 | BK-virus-associated nephropathy (A–C): intranuclear viral
inclusion in epithelial cells (B,C). Histological analysis of a kidney section
from a patient with BKV nephropathy (Trichrome Masson staining). At low
magnification (x10), note an extensive fibrosis (green staining) with an important
inflammation (Nucleus of leukocytes appeared in black). At higher magnification
(x25), the nucleus of some tubular cells is modified by the presence of a large
intranuclear viral inclusion which appeared in white (see arrows). Interstitial
infiltration is made by several mononuclear cells.
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Human Immunodeficiency Virus 1 Infected
Patients
Human immunodeficiency virus-1 infection is characterized by
severe acquired defects in the cellular immune system, which
are frequently more profound than those observed in transplant
patients in the absence of a specific antiretroviral therapy. How-
ever, very rare cases of BKV-associated nephropathy have been
observed. In contrast, although BKV reactivation is rare, these
patients sometimes have reactivation of JCV in the brain. JCV is
then responsible for PML, a rare demyelinating disease of the cen-
tral nervous system that occurs almost exclusively in patients with
severe defects in their cellular immune system. Incidence rates
have decreased with the development of highly active antiretrovi-
ral therapies (HAART): i.e., 3.3 [95%CI, 1.9–5.7] and 1.3 [95%CI,
0.8–1.9] cases per 1000 person-yearswere at risk in 1995–1996 and
in 2000–2006, respectively. However, survival after PML remains
poor (median survival time was 0.4 years [95% CI, 0.0–0.7] before
HAART and 1.8 years [95% CI, 0.6–3.0] after HAART), with
~50% mortality within 1 year of diagnosis (17) To date, there is
no specific treatment for PML or a control for JCV replication.
However, HAART has improved the prognosis for PML, probably
by facilitating restoration of the immune defect. Indeed, after
HAART initiation, an expansion of central memory CD4+ T cells
was observed in treatment–naiveHIV-infected patients andmight
be an early indicator of immune reconstitution (18).
Description of the BK-Virus
Members of polyomavirus family have a common morphology
and structure. Virions are small, non-enveloped, and appear as
icosahedral particles 40–45µm in diameter. Capsids contain cir-
cular double-stranded DNA with a 5 kb viral genome, wrapped
around the host’s cell-derived histones. Polyomavirus genomes are
more than 80% homologous. Their viral genome is divided into
three regions (2, 3):
 The non-coding control region regulates gene transcrip-
tion. At the origin of viral replication, this region regulates
expression of the early and late viral genes.
 The early gene region encodes for regulatory proteins called
the “large tumor antigen” (LTag) and “small T-antigen”
(sTag). LTag and sTag facilitate viral-genome integration and
replication by abrogating cell-cycle control. LTag is capable
of inactivating some proteins in the endoplasmic reticu-
lum, in particular the p53 protein, responsible for cell-cycle
control by inducing apoptosis. BKV is able to prevent lysis
of infected cells and has the capacity to initiate oncogenic
transformation.
 The late gene region encodes the capsid proteins: VP-1,VP-2,
and VP-3.
Polyomavirus-Specific Immunity
In Healthy People
A virus-specific cellular-immunity response is critical to control
virus replication and to prevent chronic disease. Viral infections
with a propensity for latency require continuous immune control
to restrict the rate and level of virus reactivation. T cells respond
by their cytotoxic activities and the secretion of cytokines, and
have a direct antiviral effect that is essential for the control of
chronic viruses (19). In addition, antibodies (developed during
infection) may participate in the clearance of the virus. BKV-
seropositive recipients have neutralizing antibody titers, but these
are not protective against BKV replication or BKV-associated
nephropathy (20, 21).
The targets for BKV-specific cellular immunity are wide and
T cells respond against different BKV antigens, such as VP1,
VP2, VP3, LTag, and sTag. No immunodominant antigen has
been identified (22, 23). The T-cell response of healthy BKV
seropositives individuals has been studied by ELISpot and flow
cytometry assays. Of the total tested, 75% had more than 10 spot-
forming units per 106 PBMC to at least one of the BKV-derived
peptide pools added in the assay. Positive responses were found
to peptides derived from all five major BKV proteins (VP1, VP2,
VP3, LTag, and sTag). In addition, 91% of individuals had a CD4+
mediated response, whereas only 33% generated a CD8+ T-cell
response (24).
BK-virus-specific cellular and humoral immunity in 122
immunocompetent individuals has been shown to be highly
prevalent in young individuals. BKV-specific cellular and humoral
immunity reaches its maximum in those aged between 20 and
30 years, and then declines with increasing temporal distance
from the BKV primary infection. A cellular immune response
is dominated by poly functional CD4+ T cells, which have
proliferative activity and predominantly express poly functional
cytokines (25).
Polyomavirus BK in Immunosuppressed Patients
Episodes of BKV reactivation have a complex and poorly under-
stood pathophysiology. Multiple factors have been suggested,
such as host determinants (e.g., age, BKV-sero-negativity at
pre-transplantation, specific cellular immune responses, …) and
infected tissue (e.g., permissiveness for BKV replication), virus
determinants (e.g., replicative characteristics), and exteriormodu-
lators (e.g., immunosuppressive treatment, co-infections, inflam-
matory mediators, : : :) (2).
In kidney transplantation, alteration of the BKV-specific T-
cell response plays a crucial role in the initiation and progression
of nephropathy, although we do not know the precise patho-
physiological mechanisms (26, 27). Assessment of BKV-specific
cellular immunity can be used in immunological monitoring to
manage BKV replication. Failure to develop or expand a spe-
cific cellular immune response is a central event for the initia-
tion and maintenance of BKV replication and the progression
of BKV-associated nephropathy. BKV-specific interferon (IFN)
γ-secreting T lymphocytes have been detected in the peripheral
blood of healthy seropositive individuals. On the contrary, BKV-
seropositive KT recipients treated with immunosuppressors had
significantly lower mean frequencies of specific IFN γ-secreting
T lymphocytes compared to controls, whereas no BKV-specific
IFN-γ-secreting T cells were detectable in KT patients with BKV-
associated nephropathy.
Reduction of immunosuppression in patients with BKV-
associated nephropathy was associated with the emergence of
IFN-γ-secreting T cells to the same level as that found in
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healthy controls, as well as decreased BKV loads in the plasma
and urine (21).
In 42 KT recipients with BKV viremia, secretion of IFN-γ by
T lymphocytes was demonstrated after stimulation with LTag and
VP-1. This cellular immune response was significantly higher in
patients with viral clearance compared to those with persistent or
increased viremia. VP-1 preferentially stimulated CD4+ T cells
whereas LTag preferentially stimulated CD8+ (23). CD4+ T cells
that concomitantly secrete IFN-γ/TNF-α/IL-2 were found at a
higher frequency in patients with rapid clearance of BKV, sug-
gesting a protective role for BKV-specific poly functional CD4+
T cells (22, 28). Surprisingly, in patients with BKV-associated
nephropathy, expansion of the effector memory CD4+ T cells has
been observed. These suggest that not only the control of T-cell
proliferation but those other mechanisms of differentiation may
also be involved in the control/expansion of BKV. In addition,
despite the relatively common use of immunosuppression, the
high frequency of seroprevalence in the transplant population
and the small number of patients that develop a BKV nephropa-
thy suggest that there may be individual susceptibility to BKV
replication within this population.
The quality of response to BKV has been discussed in other
studies. The frequencies of BKV-specific CD4+ T cells were sig-
nificantly higher in transplant recipients with BKV replication
compared to T-cell frequencies in age-matched healthy controls.
Interestingly, BKV replication in renal-transplant patients was
associated with a significant change in T-cell functionality, with
a lower proliferative activity and lower levels of poly functional T
cells compared to healthy controls. A decrease in triple cytokine
productive cells was observed with a concomitant increase in
cytokine-single productive cells (25). These results suggest that
the poly functionality of T cells, in response to the virus, may be
important for virus control. The incidence of BKV nephropathy
has been reported to be less frequent with the use of mTOR
inhibitors-based therapy as compared to CNIs-based therapy.
Because mTOR inhibitors impair the cell cycle and have be
reported to reduce proliferation of virus in vitro, we can specu-
late that mTor inhibitors can reduce the replication of the virus.
However, we cannot rule out that the use of mTor inhibitors could
have a lower immunosuppressive function. For example, it has
been suggested that mTOR inhibitors are associated with a higher
rate of cellular acute rejection and a higher development of anti
donor-specific antibodies and chronic humoral rejection in renal
transplant.
Interestingly, JCV is responsible for PML in HIV immunocom-
promised patients who have a CD4 deficiency, whereas JCV is
rarely responsible for disease in organ-transplant patients. Similar
to BKV, a T-cell response seems to play a key role in controlling
JCV replication. A low CD4+ T-cell count (50 cells/µL), in par-
ticular, and a naive subset with a high number of JCVDNA copies
when PML is diagnosed appear to be risk factors formortality (17,
29, 30). A critical role for JCV’s specific CD4+ T-cell responses
to control JCV infection has been reported. The recovery of the
anti-JCV T-cell response is associated with JCV clearance and
improved survival. In addition, JCV-specific cytotoxic CD8+ T-
lymphocytes (CTL) are undetectable in the active form of PML.
Early detection of JCV-specific CTL had a 87%predictive value for
subsequent JCV-control, whereas the absence of CTL had a 82%
predictive value for subsequent active PML (p= 0.0009) (31).
In PML patients, JCV-specific CD8+ cytotoxic T-lymphocytes
have been shown to overexpress Programed Cell Death-1
(PD-1), an inhibitory receptor, associated with cellular exhaus-
tion. Binding of PD-1 to its ligands, PD-L1 and PD-L2, ren-
ders T-lymphocytes anergic, preventing proliferation and the
production of interleukin-2 (IL-2). Blocking the PD-1 receptor
in vitro, increased the JCV-specific T-cell immune response in
HIV-positive patients with early PML (32). These results highlight
the different mechanisms that can be involved in virus mainte-
nance and that modulation of co-stimulation through the second
signal family may play a role in the antiviral response.
Experimental Models for Polyomavirus
To determine the role of the immune system in the control of
the polyomavirus replication, several models of viral infection
have been developed. Recently, a mouse model to study the JCV-
specific immune response has been developed in humanizedmice.
These mice are able to develop T- and B-cell-specific human
responses following contact with JCV. Six weeks after JCV inoc-
ulation, both CD4+ and CD8+ T cells overexpressed PD-1 that
was found on CD4+ and CD8+ JVC-specific T cells in patients
with PML, suggesting that JCV infection may have an effect on
immune exhaustion (33).
No animal model has been yet conducted on BKV. How-
ever, rodents are natural hosts for murine polyomavirus (MPyV).
MPyV has extensive sequence homology with the human poly-
omavirus. If the primo-infection is asymptomatic, viral reactiva-
tion occurs during episodes of immunosuppression.Mice infected
with MPyV are a good model to study the pathophysiology of
human polyomavirus infections (34, 35). Following renal trans-
plantation, these mice developed an MPyV-associated nephropa-
thy, similar to human BKV-associated nephropathy. Replication
of MPyV was greatest, almost exclusively in kidney transplant,
and was associated with renal graft loss, exacerbation of allore-
activity of CD8+ T cells, and an enhanced anti-donor T-cell
response that led to rejection (36). This replication of MPyV
occurred almost exclusively in kidney transplant, but not in
native kidneys of this renal transplant mice model. This has
raised the hypothesis that renal cells undergoing regeneration
and differentiation, because of damage induced by transplanta-
tion or because of local inflammation, became permissive to the
virus (36, 37).
Immune Antiviral Therapeutic Options
Specific Immunological Monitoring
Immuno-virological monitoring (by studying the functional
capacity of specific T cells) can be used to identify patients at risk
for infectious complications during acquired immunodeficiency
(19). The identification of a low anti viral response against BKV,
in kidney transplant could be a marker of a higher risk to develop
BKV recurrence and/or BKV nephropathy. In such cases, the
modulation of the immunosuppression during transplantation
might enable expansion of BKV-specific T cells and, thus, the
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control of viral replication. The detection of BKV-specific T cells
can be used as tool to guide immunosuppression with the aim
of controlling viral replication while also maintaining adequate
immunosuppression to prevent rejection (27).
Innovative Immune-Based Therapeutic Treatment
Immune-based therapies may further contribute to BKV control
and could be an alternative to the current treatment options in
restoring an effective viral-specific immune response. A method
for the generation of BKV-specific cytotoxic T lymphocytes from
BKV seropositive healthy donors and KT patients, based on stim-
ulation of PBMCwith dendritic cells pulsed with inactivated BKV,
has been described (38).
Ex vivo studies have shown that the generation and expan-
sion of BKV-specific T cells were possible in KT recipients
and allogeneic hematopoietic stem-cell transplant patients. These
specific lymphocytes were obtained fromhematopoietic stem cells
from healthy donors or after ex vivo expansion of BKV-specific
T cells. These cells had the ability to proliferate after antigen
re-stimulation, to produce pro-inflammatory cytokines, and to
induce cytotoxicity in vitro (39).
Another immune-based therapy could be developed from vac-
cines. Finding immunodominant peptides would be of interest in
this context to develop a peptide vaccination.
In addition, identification of the role of the PD1/PDL1-L2
receptor, a member of the second signal activation family, during
JCV infection opens up new perspectives. During JCV infection,
PD1 expressed by infected cells impairs T-cell activation and virus
control. Regulation of this pathway or inhibition of its signal could
be potentially helpful and control viral replication. However, its
modulation in transplant patients could be associated with wider
activation of T-cell function, leading to acute rejection.
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